These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7496802)

  • 1. Central cardiovascular and behavioral effects of carboxy- and amino-terminal fragments of substance P in conscious rats.
    Tschöpe C; Jost N; Unger T; Culman J
    Brain Res; 1995 Aug; 690(1):15-24. PubMed ID: 7496802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.
    Culman J; Wiegand B; Spitznagel H; Klee S; Unger T
    Br J Pharmacol; 1995 Mar; 114(6):1310-6. PubMed ID: 7542533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P and neurokinin A induced desensitization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors.
    Culman J; Tschöpe C; Jost N; Itoi K; Unger T
    Brain Res; 1993 Oct; 625(1):75-83. PubMed ID: 7694777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
    Cellier E; Barbot L; Regoli D; Couture R
    Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
    Picard P; Regoli D; Couture R
    Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats.
    Itoi K; Tschöpe C; Jost N; Culman J; Lebrun C; Stauss B; Unger T
    Eur J Pharmacol; 1992 Sep; 219(3):435-44. PubMed ID: 1385176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.
    Tschöpe C; Picard P; Culman J; Prat A; Itoi K; Regoli D; Unger T; Couture R
    Br J Pharmacol; 1992 Nov; 107(3):750-5. PubMed ID: 1335337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.
    Picard P; Couture R
    Br J Pharmacol; 1996 Jan; 117(2):241-9. PubMed ID: 8789375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress.
    Culman J; Klee S; Ohlendorf C; Unger T
    J Pharmacol Exp Ther; 1997 Jan; 280(1):238-46. PubMed ID: 8996202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place aversion induced by microinjections of C-fragment of substance P into the dorsal periaqueductal gray of rats is mediated by tachykinin NK1 receptors.
    De Araújo JE; Huston JP; Brandão ML
    Peptides; 2001 Sep; 22(9):1447-52. PubMed ID: 11514027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.
    Cellier E; Barbot L; Iyengar S; Couture R
    Br J Pharmacol; 1999 Jun; 127(3):717-28. PubMed ID: 10401563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition by morphine of the cardiovascular and behavioral responses evoked by centrally administered substance P in conscious rats.
    Itoi K; Jost N; Tschöpe C; Culman J; Badoer E; Unger T
    Neuropharmacology; 1994 Feb; 33(2):181-7. PubMed ID: 7518572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plus-maze in rats.
    Duarte FS; Testolin R; De Lima TC
    Behav Brain Res; 2004 Oct; 154(2):501-10. PubMed ID: 15313039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-FOS expression in the rat brain in response to substance P and neurokinin B.
    Spitznagel H; Baulmann J; Blume A; Unger T; Culman J
    Brain Res; 2001 Oct; 916(1-2):11-21. PubMed ID: 11597586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats.
    Diamant M; Kashtanov SI; Fodor M; de Wied D
    Neuroendocrinology; 1992 Nov; 56(5):750-60. PubMed ID: 1488107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxytocin pathways mediate the cardiovascular and behavioral responses to substance P in the rat brain.
    Maier T; Dai WJ; Csikós T; Jirikowski GF; Unger T; Culman J
    Hypertension; 1998 Jan; 31(1 Pt 2):480-6. PubMed ID: 9453349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinforcing effects of neurokinin substance P in the ventral pallidum: mediation by the tachykinin NK1 receptor.
    Nikolaus S; Huston JP; Hasenöhrl RU
    Eur J Pharmacol; 1999 Apr; 370(2):93-9. PubMed ID: 10323256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization.
    Prat A; Picard P; Couture R
    Br J Pharmacol; 1994 May; 112(1):250-6. PubMed ID: 7518305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
    Tauer U; Zhao Y; Hunt SP; Culman J
    Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.
    Piot O; Betschart J; Grall I; Ravard S; Garret C; Blanchard JC
    Br J Pharmacol; 1995 Nov; 116(5):2496-502. PubMed ID: 8581290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.